�Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from an ongoing Phase I/II clinical trial of ispinesib are scheduled to be presented as a bill sticker presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September 57, 2008 at the Hilton Washington in Washington, DC.
In June 2008, as part of a bill poster session at the ASCO Annual Meeting, Cytokinetics proclaimed interim data from the Phase I portion of its on-going Phase I/II clinical trial of ispinesib, a novel kinesin spindle protein (KSP) inhibitor, administered as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast cancer. The authors concluded that preliminary data suggest that ispinesib is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to 12 mg/m2. Results from extra patients enrolled in the ongoing Phase I, dose-escalation portion of this clinical trial are scheduled to be presented the 2008 ASCO Breast Cancer Symposium.
Poster Presentation at ASCO Breast Cancer Symposium
Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster Presentation on Friday, September 5, 2008, during the General Poster Session, 5:30 pm - 6:45 pm Eastern Time). The poster testament be ground in the Exhibit Hall at post-horse board #A50 and presented by Henry Gomez, MD from Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may handle areas of significant unmet clinical inevitably. Cytokinetics' cardiovascular disease programme is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alignment established in 2006, Cytokinetics and Amgen Inc. ar performing joint research focused on identifying and characterizing activators of cardiac myosin as patronage and follow-on potential do drugs candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialise CK-1827452, topic to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer curriculum is focussed on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alignment established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting inquiry and development activities focused on the potential discourse of genus Cancer. Cytokinetics is developing deuce novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical run of ispinesib as monotherapy as a first-line discussion in chemotherapy-na�ve patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the join development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative inquiry activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is existence developed under the strategical alliance by GSK; GSK began a Phase I clinical trial run with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potency drug campaigner directed towards skeletal muscle contractility which may be developed as a voltage treatment for skeletal muscle weakness associated with neuromuscular diseases or other weather. All of these do drugs candidates and potential drug candidates hold arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a composite biological base that plays a rudimentary role inside every human cell. Additional information about Cytokinetics lavatory be obtained at hTTP://www.cytokinetics.com.
This press release contains advanced statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any design or obligation to update these modern statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, merely are non limited to, statements relating to Cytokinetics' research and development programs, including plotted presentations relating to clinical trial results, and the properties and potential benefits of Cytokinetics' drug candidates and electric potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential drop difficulties or delays in the development, testing, regulative approval or production of Cytokinetics' drug candidates that could slow or foreclose clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be declarative of future clinical trials results, affected role enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate remedial efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies whitethorn delay or limit Cytokinetics' or its partners' ability to carry on clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur out of the blue research and development and other costs or be unable to obtain extra financing necessary to conduct development of its products; standards of care whitethorn change and others may introduce products or alternative therapies for the intervention of indications Cytokinetics' do drugs candidates and potential do drugs candidates whitethorn target; and risks and uncertainties relating to the timing and receipt of payments from Cytokinetics' partners, including milestones and royalties on future potential product sales under its coaction agreements with such partners. For further information regarding these and other risks related to Cytokinetics' patronage, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Cytokinetics
More info
Subscribe to:
Posts (Atom)